source
- Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseasesBiogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
- AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trialAriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…